A new continuing education course from Pharmacy Times Continuing Education is shining a spotlight on the evolving treatment landscape for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) – and on the pharmacists who are helping lead the way. Among them is Abby Kim, whose expert guidance plays a central role in the course’s success.  

Titled “Updated Guidance and Managed Care Strategies to Optimize Care in EGFR-Mutated NSCLC,” the course equips pharmacists with the latest knowledge on how to personalize treatment for patients with EGFR mutations. These mutations drive cancer growth and require therapies that are precisely targeted to the tumor’s biology.  

Abby Kim brings deep clinical insight to the course, helping participants understand how biomarker testing can unlock better treatment decisions. Her contributions focus on how pharmacists can interpret test results, identify the most effective therapies, and advocate for timely and equitable access to care. She also helps learners navigate the complexities of emerging treatments like antibody-drug conjugates and tyrosine kinase inhibitors – cutting-edge options that are changing the standard of care. 

Kim’s involvement ensures that the course goes beyond theory. Through her real-world experience, she highlights the pharmacist’s role in multidisciplinary teams, formulary management, and patient education. Her perspective helps learners see how they can influence outcomes not just at the pharmacy counter, but across the entire care continuum. 

The course also explores broader issues such as disparities in biomarker testing, cost-effectiveness of therapies, and strategies to reduce variability in care. With Kim’s guidance, pharmacists are empowered to take a leadership role in addressing these challenges. 

For pharmacists looking to stay current in oncology care, this CE course offers more than just continuing education – it offers a chance to learn directly from one of the field’s rising voices. Abby Kim’s contributions make the material practical, actionable, and deeply relevant to today’s healthcare environment. 

Read the full article published in the August 2025 issue of AJMC - The American Journal of Managed Care Evidence-Based Oncology™.